The PARAGON-HF and PARADIGM-HF trials demonstrated that the efficacy of sacubitril/valsartan vs. renin-angiotensin inhibition, on top of beta-blockers and mineralocorticoid receptor antagonists (MRA), varies with LVEF. The gene discussed is NR3C2; the disease is hydrops fetalis.